View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Ahmed Ben Salem
  • Ahmed Ben Salem

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/15/2024

Swiss-based Accelleron was formed from the spin-off of ABB’s highly profitable turbocharger division in 2022. We view the share as a promising investment on 1/ market leadership in an attractive niche, 2/ about ~40% ROCE, 3/ conversion of ~80% of EBITDA into cash, leading to fast deleveraging, and a solid base for shareholder remuneration (75% pay out), and 4/ strong long-term visibility linked to a ~75% service share, the bulk of which is recurring. Despite an already strong stock pe...

Lynn Hautekeete
  • Lynn Hautekeete

Home Invest Belgium Model update after 3Q24 and Brussels legislation

The 3Q24 results are slightly above our expectations on the back of an improved operating margin. The guidance of EUR 1.15 EPRA EPS is reiterated. Home invest is one of the best performers to date among Belgian REITs. However, in the last month there was profit taking and negative news on regulation. As of 01/11/2024, rent increases in Brussels (66% portfolio) are on hold for 9 consecutive years. This was already the case for the 3-6-9 contracts but now impacts short term contracts and tenant de...

Guy Sips ... (+6)
  • Guy Sips
  • Hilde Van Boxstael
  • Lynn Hautekeete
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi
Lynn Hautekeete
  • Lynn Hautekeete

Nextensa 3Q24 results: improved metrics, short average duration credit...

The message at 3Q24 results is the same as in 1H24: residential sales in Belgium are moving forward, Luxembourgh RESI is at a standstill. Luckily there are almost no speculative developments in Nextensa's pipeline and its debt ratio is below 50%, at 45.6%. The average duration of the credit lines is short at 2.09y. However all FY24-1H25 maturing debts are renegotiated. The standing asset portfolio is performing well and gives comfort. The rental income increased vs 3Q23 despite divestments on th...

Cor Kluis
  • Cor Kluis

Aegon : New SBB, Q3 OCG better, increased OCG target FY24, Q3 sales wa...

>Conclusion: New SBB, Q3 OCG better, higher OCG target, Q3 sales was less - It was positive that Aegon announced a new € 150m SBB which we expected, but not all in the market was expecting this we believe. And related to that it is good Aegon announced now to bring the cash at holding down from about est. € 1.7bn end 2024 to about € 1bn end 2026 giving more room for new SBB’s. The Q3 OCG capital generation was better than expected. The Solvency was marginally less. Th...

Guy Sips
  • Guy Sips

EVS Broadcast Equipment FY24 revenue and EBIT guidance firming up towa...

EVS indicated that after 3Q24 they are on track to achieve FY24 revenue and profit at the higher end range of its guidance (revenue guidance of € 190 to €200m (KBCSe € 197.1m) and EBIT guidance €40 to 46m (KBCSe € 44.1m)). Next to the positive impact of its revenue performance on its gross profit, EVS sees an increasing gross margin performance on all its solutions. For this EVS refers to a well balanced pricing strategy. Without giving exact numbers, they highlight that this results in an overa...

Wim Lewi
  • Wim Lewi

Elia Group Politics cloud the need for investments, but no turning bac...

Elia suffers from negative downdraft as politics cast doubt on the expected RAB growth outlined in the grid development plans. In Belgium, there is currently a standstill in the government formation and in Germany an early election has been called. Also the rhetoric of president-elect Mr Trump does not bode well for US energy transition investments. For Elia specific, the Elisabeth Island and its budget have been subject of discussions that juggle with figures that are taken out of context. As t...

 PRESS RELEASE

EVS Q3 2024 business update

EVS Q3 2024 business update EVS Q3 2024 business update Reaffirming growth expectations for 2024, setting a new revenue high for EVS, while actively building the future Liège, Belgium | November 14th, 2024 EVS’ financial results are firming up in line with expectations. While the final weeks of production and deliveries are being planned, we primarily focus on building the future. Order intake for the fourth quarter looks promising, ensuring a kick start in 2025. We have significant commercial opportunities in the pipeline, which are bound to play a substantial role in our future suc...

 PRESS RELEASE

Nextensa: Q3 RESULTS 2024

Nextensa: Q3 RESULTS 2024 REGULATED INFORMATION Brussels, 14 November 2024, 5:40 PM Q3 RESULTS 2024 HIGHLIGHTS  INVESTMENT PROPERTIES The rental income is €750K higher than in the third quarter of 2023 despite the strategic divestments of Hygge and Foetz in 2024.  Realisation of a like-for-like rental growth on the entire portfolio of +2.94% in Q3 2024 compared to 2023.  Decrease in property costs by 15% (€1.5 M) due to higher occupancy rates and the aforementioned divestments.  DEVELOPMENT PROJECTS The result of the development projects is €0.6 M higher than in the same period last...

 PRESS RELEASE

Nextensa: RÉSULTATS Q3 2024

Nextensa: RÉSULTATS Q3 2024 INFORMATION RÉGLEMENTÉE Bruxelles, 14 novembre 2024, 17h40 RÉSULTATS Q3 2024 FAITS MARQUANTS IMMEUBLES DE PLACEMENT Les revenus locatifs sont supérieurs de 750K € à ceux du troisième trimestre 2023 malgré les désinvestissements stratégiques de Hygge et Foetz en 2024. Réalisation d’une croissance des loyers à périmètre constant sur l’ensemble du portefeuille de +2,94 % au Q3 2024 par rapport à 2023. Diminution des coûts immobiliers de 15 % (1,5 million d’euros) en raison de taux d’occupation plus élevés et des désinvestissements susmentionnés. PROJETS DE D...

Reg Watson ... (+2)
  • Reg Watson
  • CFA

dsm-firmenich/Take your vitamins/BUY

dsm-firmenich expects to separate its Animal Nutrition and Health (ANH) business in 2025 which will complete the company's transformation into a flavours and fragrances business to rival Givaudan and Symrise. We model the impact of this on valuation and forecast the expected short-term boost from vitamin pricing. The outcome is that our adj. EBITDA forecasts for 2024-25F rise by c.10% each year but our valuation declines slightly to €146 per share, based on the disposal of ANH. We maintain our B...

Guy Sips ... (+11)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update November 2024 – Adding Azelis – Removing ...

With 2 changes in our Dynamic Top Pick list (we add Azelis and we remove Solvay) we maintain a defensive stance on the market for 2H24. The long anticipated interest rate cuts by central banks have finally started. The Trump election victory in the US does not bode well for European stocks as he favours a protectionist course. Although industrial companies with a US base could actually benefit. Cleantech names with exposure to the US could also suffer (unless owned by E.Musk). We expect the US ...

Jason Kalamboussis
  • Jason Kalamboussis

AEGON/Turning the page/BUY

AEGON is starting to move more firmly away from its restructuring and legacy books and looks set to embrace a path focusing more on growth, notably in the US, organically and also possibly externally through M&A. Increasing cash generation and fungibility results in Share Buybacks that we now expect to be €300m per annum, but with potential to increase should AEGON decide to lower its cash balance upper end need to €1bn. The ASR stake is finally increasing in value, while new CFO Duncan Russell ...

Wim Hoste
  • Wim Hoste

DSM-Firmenich Conference call feedback

Below are the highlights from the 3Q results conference call. 3Q adjusted EBITDA jumped 32% and beat our and consensus by respectively 3% and 1%. Dsm-firmenich increased FY24 adj EBITDA guidance from c € 2bn to towards € 2.1bn, citing disruption in the vitamin market. We remind that the recently announced mid term financial targets for the new scope (ie ex ANH) are similar to the targets of the current group, ie 5-7% organic sales growth and an 22-23% adjusted EBITDA margin, which represent a si...

Wim Hoste
  • Wim Hoste

DSM-Firmenich FIRST LOOK: 3Q adj.EBITDA +32%, FY guidance up to ‘towar...

3Q adjusted EBITDA jumped 32% and beat our and consensus by respectively 3% and 1%. Dsm-firmenich increased FY24 adj EBITDA guidance from c € 2bn to towards € 2.1bn, citing disruption in the vitamin market. We remind that the recently announced mid term financial targets for the new scope (ie ex ANH) are similar to the targets of the current group, ie 5-7% organic sales growth and an 22-23% adjusted EBITDA margin, which represent a sizeable step-up to the FY23 margin level of c. 18% (ex ANH). We...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Aalberts: 3Q24 preview - no signs of recovery expected. AB InBev: All to play for in the final quarter. Arcadis: A mixed bag. Ayvens: Struggling to get out of neutral. dsm-firmenich: Taking your vitamins is healthy. D'Ieteren: Belron equity at €23.5bn, EV €32.2bn in minority shareholder transaction. Euronext: 3Q24 and CMD Preview. Flow Traders: Bumper harvest. Heijmans: 3Q24 as expected, keeps FY outlook in place. Proximus: Key politician pushing for major governance shake up. ...

Stefano Toffano
  • Stefano Toffano

DSM-Firmenich : Further signs of broad end-market normalisation

>Continued demand recovery - dsm-firmenich’s Q3 24 results once again confirmed the improving business momentum. The company posted another sequential good quarter on the back of a.o. easing comps, improving demand and the continued realisation of self-help benefits. While the strong positive impact on vitamin prices is temporary and will take some time to fully feed through, the higher vitamin pricing environment (a.o.) pushed ANH profitability higher, albeit from a ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch